Replies to post #609 on VBI Vaccines Inc (VBIV)

[cheynew]

Late-Breaker Oral Presentation

Abstract #: AS169
Title: High HBsAb titers consistent across 3 lots of the tri-antigenic HepB Vaccine, Sci-B-Vac®: Results from the second pivotal Phase 3 double-blind, randomized controlled trial designed to assess the lot-to-lot consistency of Sci-B-Vac® in adults (CONSTANT)
Session: Abstract Session: HBV – Clinical
Date: Saturday, August 29, 2020
Time: 12:15 – 12:30 CEST
Presenter: Adam Finn, M.D., Ph.D., Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study
Event Website: https://ilc-congress.eu/
The oral presentation will be displayed as a 10-minute pre-recorded video followed by a five-minute live Q&A session.